CLSD - Clearside Biomedical, Inc.
| Previous Close | 1.0600 |
| Open | 1.0500 |
| Bid | 1.0100 x 2200 |
| Ask | 1.1300 x 1800 |
| Day's Range | 1.0262 - 1.0800 |
| 52 Week Range | 0.9500 - 11.2450 |
| Volume | 258,583 |
| Avg. Volume | 442,701 |
| Market Cap | 39.099M |
| Beta (3Y Monthly) | -0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5060 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- GlobeNewswire•5 days ago
Clearside Biomedical to Present at the JMP Securities Life Sciences Conference
ALPHARETTA, Ga., June 11, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CLSD earnings conference call or presentation 8-May-19 12:30pm GMT
Q1 2019 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•last month
Clearside Biomedical to Present at the UBS Global Healthcare Conference
ALPHARETTA, Ga., May 15, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision.
- GlobeNewswire•last month
Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and provided a corporate update. “Clearside has a compelling opportunity to leverage our innovative, non-surgical suprachoroidal space (SCS) delivery platform to make a difference for patients with sight-threatening diseases in the U.S. and around the world,” said George Lasezkay, Pharm.D., J.D., Clearside’s Interim Chief Executive Officer. Dr. Lasezkay continued, “We are validating our platform with the potential approval of our first product candidate, XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis, a condition that currently has no approved therapies.
- GlobeNewswire•2 months ago
Clearside Biomedical’s Suprachoroidal Space Injection Platform Featured at Multiple Ophthalmology and Gene Therapy Medical Meetings
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations were made on Clearside’s Suprachoroidal Space (SCS) injection platform at ophthalmology and gene therapy medical meetings in Vancouver, British Columbia. The presentations highlighted the potential benefits of Clearside’s SCS injection platform when utilized in uveitis patients and with gene therapy.
- GlobeNewswire•2 months ago
Clearside Biomedical to Report First Quarter 2019 Financial Results and Provide Corporate Update on Wednesday, May 8, 2019
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its first quarter 2019 financial results will be reported on Wednesday, May 8, 2019. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 7816049. An archive of the webcast will be available for three months. Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases.
- GlobeNewswire•2 months ago
Clearside Biomedical Announces Multiple Presentations on its Suprachoroidal Space® Injection Platform at Upcoming Medical Meetings
ALPHARETTA, Ga., April 18, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire•2 months ago
Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEO
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Board of Directors has appointed seasoned biopharmaceutical executive George Lasezkay, Pharm.D., J.D. to the position of Interim Chief Executive Officer, effective immediately. Dr. Lasezkay, a current member of the Clearside Board of Directors, succeeds Daniel H. White, who resigned as President and CEO and as a member of the Board of Directors to pursue other opportunities.
- GlobeNewswire•2 months ago
Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference
ALPHARETTA, Ga., April 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CLSD earnings conference call or presentation 12-Mar-19 9:00pm GMT
Q4 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•3 months ago
Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA Date -- Management to Host.
- GlobeNewswire•3 months ago
Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference
ALPHARETTA, Ga., March 04, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire•4 months ago
Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019
ALPHARETTA, Ga., Feb. 27, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Simply Wall St.•4 months ago
Do Insiders Own Shares In Clearside Biomedical, Inc. (NASDAQ:CLSD)?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Clearside Biomedical, Inc. (NASDAQ:CLSD) should be awareRead More...
- ACCESSWIRE•4 months ago
Four Tech Stocks Bubbling with Excitement
ParcelPal Technology Inc (PTNYF) (PKG), Clearside Biomedical Inc (CLSD), ACM Research Inc (ACMR), and Everspin Technologies (MRAM) are four tech companies exemplifying what it means to be forward-thinking. ParcelPal Technology Inc (PTNYF) (PKG) was, like many other tech companies, born out of a desire to solve a systemic issue, but where the Company rises above the rest is in their core framework and execution. ParcelPal's founders recognized an apparent need for consumers to have increased access to the products and goods they use on a daily basis, so they created an on-demand marketplace where customers can purchase nearly any product on the market and have it delivered within the hour.
- GlobeNewswire•4 months ago
Recent Analysis Shows Cisco, Zendesk, Clearside Biomedical, Conn's, NIC, and Commercial Vehicle Group Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the Agency has accepted for review the New Drug Application (NDA) for XIPERE (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The FDA has determined that the application is sufficiently complete to permit a substantive review.
- GlobeNewswire•4 months ago
Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations were given at the 42nd Annual Macula Society Meeting held February 13-16, 2019 in Bonita Springs, Florida. The four scientific presentations reviewed clinical and nonclinical data analyses of Clearside programs in multiple disease states, including macular edema associated with uveitis and diabetic macular edema (DME), as well as gene therapy. Dr. Steven Yeh, Associate Professor, Emory Eye Center, stated, “Suprachoroidal injections are a novel drug delivery approach with high selectivity for the retina and choroid.
- ACCESSWIRE•4 months ago
Healthcare Companies Positioned in Major Markets
HENDERSON, NV / ACCESSWIRE / February 15, 2019 / Pain relief medicines are a massive market 30 billion doses of which are consumed each year in the US alone. Opioids like codeine and hydrocodone are also ...
- GlobeNewswire•5 months ago
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center.
- GlobeNewswire•5 months ago
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
ALPHARETTA, Ga., Jan. 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Simply Wall St.•6 months ago
Need To Know: Clearside Biomedical, Inc. (NASDAQ:CLSD) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
- GlobeNewswire•6 months ago
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
Approximately one-third of these patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location - anterior, intermediate, posterior or pan. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of CLSD earnings conference call or presentation 8-Nov-18 1:30pm GMT
Q3 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•7 months ago
Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
